Increased influenza pneumonia mortality of mice adoptively immunized with node and spleen cells sensitized by inactivated but not live virus.
Syngeneic mice adoptively immunized intravenously with 25 million washed node and spleen cells from donors vaccinated subcutaneously with formolized influenza A PR8 had a higher mortality with influenza pneumonia after challenge with homologous virus than occurred in recipients of similar cells from unsensitized donors, and this increased mortality was prevented by treatment of the sensitized cells with antithymocyte serum. Mice adoptively immunized with cells from donors vaccinated with formolized influenza A PR8 also had a higher mortality than recipients of unsensitized cells after challenge with heterologous influenza B Lee. Mice who received PR8-sensitized cells and survived challenge with influenza B Lee developed antibody only to the challenge virus, and serum antibody titers to the challenge virus in surviving recipients of sensitized cells were similar to those of recipients of unsensitized cells in all studies. Influenza mortality of recipients of antibody-containing mouse serum after homologous virus challenge was similar to that of recipients of antibody-free mouse serum in this model. Washed node and spleen cells from donor mice who had survived respiratory infection or received subcutaneous vaccination with live influenza A PR8 and those from donor mice given typhoid vaccine subcutaneously all failed to alter mortality from that observed in recipients of unsensitized cells after challenge with influenza A PR8. These results suggest that subcutaneous vaccination with inactivated influenza establishes a reactivity of  the cell-mediated immunologic system which can increase the severity of influenza infection of the respiratory tract under certain conditions, and that sensitization by live influenza fails to produce this effect.
D000818:Animals; D000961:Antilymphocyte Serum; D000939:Epitopes; D006386:Hemagglutination Tests; D007112:Immunity, Maternally-Acquired; D007114:Immunization; D007117:Immunization, Secondary; D007252:Influenza Vaccines; D008198:Lymph Nodes / Q000166:cytology; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D009975:Orthomyxoviridae / Q000276:immunology*; D009976:Orthomyxoviridae Infections / Q000276:immunology*; D011817:Rabbits / Q000276:immunology; D013154:Spleen / Q000166:cytology; D013950:Thymus Gland / Q000276:immunology; D014436:Typhoid-Paratyphoid Vaccines; D014613:Vaccines, Attenuated
D000961:Antilymphocyte Serum; D000939:Epitopes; D007252:Influenza Vaccines; D014436:Typhoid-Paratyphoid Vaccines; D014613:Vaccines, Attenuated